Troubled Ventracor Of Australia Answers Critics Over Heart Pumps
This article was originally published in PharmAsia News
Executive Summary
Australia's Ventracor denied accusations to the contrary and said it complied fully with federal rules in three instances in which patients died after being implanted with its heart pumps. The company has been accused of delaying notices to investors about problems, which led to an ordered halt to trading in its stock. Ventracor says the three deaths were reported to health authorities and it was not required to disclose them to the stock market. It also said the fractures in its pumps in the three cases were caused by "accidental trauma" and that in eight other non-fatal incidents, the implanted patients were not wearing their support belts. (Click here for more
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.